enoxacin has been researched along with Acute Confusional Senile Dementia in 31 studies
Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.
enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Considering the complex etiology of Alzheimer's disease (AD), multifunctional agents may be beneficial for the treatment of this disease." | 1.46 | DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy. ( Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y, 2017) |
| "Alzheimer's disease is the most common cause of dementia." | 1.42 | In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier. ( Cahlíková, L; Chlebek, J; Hošt'álková, A; Opletal, L; Pérez, DI; Šafratová, M; Štěpánková, Š, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (9.68) | 29.6817 |
| 2010's | 27 (87.10) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Marco-Contelles, J | 1 |
| León, R | 3 |
| de los Ríos, C | 1 |
| Samadi, A | 1 |
| Bartolini, M | 2 |
| Andrisano, V | 3 |
| Huertas, O | 2 |
| Barril, X | 1 |
| Luque, FJ | 2 |
| Rodríguez-Franco, MI | 5 |
| López, B | 3 |
| López, MG | 4 |
| García, AG | 3 |
| Carreiras, Mdo C | 1 |
| Villarroya, M | 4 |
| Camps, P | 1 |
| Formosa, X | 1 |
| Galdeano, C | 1 |
| Muñoz-Torrero, D | 1 |
| Ramírez, L | 1 |
| Gómez, E | 1 |
| Isambert, N | 1 |
| Lavilla, R | 1 |
| Badia, A | 1 |
| Clos, MV | 1 |
| Mancini, F | 2 |
| Arce, MP | 4 |
| Dafni, T | 1 |
| González-Muñoz, GC | 2 |
| Pérez, C | 3 |
| Conde, S | 3 |
| Romero, A | 1 |
| del Barrio, L | 1 |
| Martín-de-Saavedra, MD | 1 |
| Egea, J | 2 |
| Tang, H | 3 |
| Zhao, LZ | 1 |
| Zhao, HT | 2 |
| Huang, SL | 1 |
| Zhong, SM | 2 |
| Qin, JK | 1 |
| Chen, ZF | 2 |
| Huang, ZS | 1 |
| Liang, H | 2 |
| Chiriano, G | 1 |
| De Simone, A | 1 |
| Perez, DI | 2 |
| Cavalli, A | 1 |
| Bolognesi, ML | 1 |
| Legname, G | 1 |
| Martinez, A | 1 |
| Carloni, P | 1 |
| Roberti, M | 1 |
| Wang, ZY | 1 |
| Sang, Z | 11 |
| Li, Y | 10 |
| Qiang, X | 9 |
| Xiao, G | 6 |
| Liu, Q | 2 |
| Tan, Z | 11 |
| Deng, Y | 10 |
| Cahlíková, L | 1 |
| Štěpánková, Š | 1 |
| Chlebek, J | 1 |
| Šafratová, M | 1 |
| Hošt'álková, A | 1 |
| Opletal, L | 1 |
| Luo, L | 5 |
| Wei, S | 1 |
| Chen, W | 1 |
| Qin, J | 1 |
| Huangli, Y | 1 |
| Wang, L | 1 |
| Shen, Y | 1 |
| Yang, X | 4 |
| Zheng, Y | 4 |
| Cao, Z | 5 |
| Su, F | 2 |
| Ai, J | 1 |
| Xu, R | 4 |
| Monjas, L | 1 |
| Gil, C | 1 |
| Pan, W | 2 |
| Wang, K | 8 |
| Ma, Q | 4 |
| Yu, L | 4 |
| Yang, Y | 1 |
| Bai, P | 2 |
| Leng, C | 1 |
| Xu, Q | 1 |
| Li, X | 2 |
| Liu, W | 10 |
| Wang, H | 6 |
| Ye, M | 2 |
| Han, X | 2 |
| Xu, YX | 1 |
| Li, XK | 1 |
| Dong, SN | 1 |
| Liu, WW | 1 |
| Gong, Q | 2 |
| Wang, TD | 1 |
| Tang, Y | 1 |
| Zhu, J | 2 |
| Li, J | 2 |
| Zhang, HY | 1 |
| Mao, F | 2 |
| Yang, J | 2 |
| Song, Q | 4 |
| Zhang, X | 2 |
| Liu, H | 4 |
| Yang, Z | 2 |
| Xu, Y | 1 |
| Zhang, J | 1 |
| Wang, W | 1 |
| Qiu, X | 1 |
| Zhang, H | 1 |
| Tian, C | 1 |
| Li, W | 1 |
| He, Y | 1 |
| Ye, C | 1 |
| Shi, J | 4 |
| Zhang, P | 3 |
| Zhu, G | 1 |
| Yang, D | 1 |
| Fan, X | 1 |
| Zhang, Z | 1 |
| Cheng, X | 1 |
| Zhang, Q | 1 |
| Zheng, C | 1 |
| Cheng, Y | 1 |
| Lu, X | 1 |
| Liu, X | 1 |
| Tian, L | 1 |
| Gao, Y | 1 |
| Chen, H | 1 |
| Jiang, X | 1 |
| Xu, Z | 1 |
| Ding, H | 1 |
| Zhao, Q | 1 |
31 other studies available for enoxacin and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholines | 2009 |
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases | 2009 |
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cataly | 2009 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cel | 2011 |
Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Aporphines; Blood- | 2011 |
A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cell Surviv | 2012 |
Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Binding Sites; Blood-Bra | 2012 |
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Blood-Brain Barrier; Butyr | 2015 |
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
Topics: Acetylcholinesterase; Alzheimer Disease; Amaryllidaceae Alkaloids; Biological Transport; Blood-Brain | 2015 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; C | 2016 |
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Autophagy; Cholinesteras | 2016 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; D | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inh | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Bloo | 2017 |
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Don | 2017 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholine | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholin | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Chol | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood- | 2017 |
Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2018 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Surviva | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Br | 2018 |
Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholin | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N | 2018 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cho | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyry | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase I | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Developm | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Tr | 2019 |
Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Dyr | 2021 |